STOCK TITAN

Incyte Genomics (INCY) Financials

INCY NASDAQ
Trailing 12 months to September 30, 2026
Revenue $6.0B +24.9% YoY
Net Income $403.4M -66.1% YoY
EPS (Diluted) $1.88 -68.1% YoY
Operating Cash Flow $745.0M -40.5% YoY
Market Cap $23.4B as of Nov 20, 2026
Price / Sales 3.9x on $6.0B revenue, trailing 12 months to September 30, 2026
Price / Earnings 57.9x on $403.4M net income, trailing 12 months to September 30, 2026
Price / Book 4.1x on $5.6B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INCY SEC filings page.

Incyte Genomics Inc (INCY) reported $6.0B in revenue over the twelve months to Sep 30, 2026, up 24.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INCY FY2025

Incyte’s earnings rebounded sharply in FY2025 as reduced R&D spending let growing revenue flow through to operating profit and cash.

FY2024 paired R&D of $2.61B with an operating margin of 1.5%, so the near-zero profit profile reflected spending intensity more than weak sales. In FY2025, R&D fell 21.4% and operating margin reached 29.5%, revealing how quickly reported earnings respond when that investment load eases.

FY2025 operating cash flow of $1.41B exceeded net income of $1.29B, so earnings were accompanied by cash rather than relying mainly on accruals. The 109.9% conversion ratio and 3.3x current ratio together point to cash-backed earnings and a strengthened short-term balance-sheet position.

The FY2024 buyback totaled $2.00B while equity fell to $3.45B, making capital return a major balance-sheet event. By FY2025, buybacks were $0 and liabilities were 25.7% of assets, so the balance sheet had rebuilt equity without increasing leverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 75 / 100
Financial Health Score (5 of 6 dimensions) 75/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Incyte Genomics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
72

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Incyte Genomics Inc scores 72/100 on it among other operating companies.

Growth
79

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Incyte Genomics Inc scores 79/100 on it among other operating companies.

Leverage
67

Incyte Genomics Inc carried $0.35 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, Incyte Genomics Inc is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 67/100 among other operating companies measured the same way.

Liquidity
82

Incyte Genomics Inc held $3.32 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 3.32. Liquidity ranks operating companies on that ratio, and Incyte Genomics Inc scores 82/100 among other operating companies.

Cash Flow
n/a

Not available for Incyte Genomics Inc, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

Returns
73

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Incyte Genomics Inc scores 73/100 on it among other operating companies.

Altman Z-Score Safe
9.93

Incyte Genomics Inc scores 9.93, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $23.4B against total liabilities of $1.8B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
6/8

Incyte Genomics Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed
1.10x

For every $1 of reported earnings, Incyte Genomics Inc generates $1.10 in operating cash flow ($1.4B OCF vs $1.3B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
623.91x

Incyte Genomics Inc earns $623.91 in operating income for every $1 of interest expense ($1.5B vs $2.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.6B
YoY+14.0%
QoQ-7.0%
5Y CAGR+13.9%
10Y CAGR+19.2%

Incyte Genomics Inc generated $1.6B in revenue in Q3 2026. This represents an increase of 14.0% from the same quarter a year earlier. Against the prior quarter it is down 7.0%.

EBITDA
-$684.2M
YoY-246.3%
QoQ-194.5%

Incyte Genomics Inc's EBITDA was -$684.2M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 246.3% from the same quarter a year earlier. Against the prior quarter it is down 194.5%.

Net Income
-$784.8M
YoY-285.0%
QoQ-234.0%

Incyte Genomics Inc reported a net loss of $784.8M in Q3 2026. This represents a decrease of 285.0% from the same quarter a year earlier. Against the prior quarter it is down 234.0%.

EPS (Diluted)
-$3.86
YoY-282.9%
QoQ-237.4%

Incyte Genomics Inc earned -$3.86 per diluted share (EPS) in Q3 2026. This represents a decrease of 282.9% from the same quarter a year earlier. Against the prior quarter it is down 237.4%.

Cash & Balance Sheet

Cash & Debt
$3.3B
YoY+33.4%
QoQ-17.7%
5Y CAGR+10.4%
10Y CAGR+18.9%

Incyte Genomics Inc held $3.3B in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
204M
YoY+3.8%
QoQ+0.6%
5Y CAGR-1.6%
10Y CAGR+0.8%

Incyte Genomics Inc had 204M shares outstanding in Q3 2026. This represents an increase of 3.8% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
93.0%
YoY+0.3pp
QoQ-0.7pp
5Y change-2.1pp

Incyte Genomics Inc's gross margin was 93.0% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.

Operating Margin
-45.5%
YoY-78.0pp
QoQ-87.2pp
5Y change-74.5pp

Incyte Genomics Inc's operating margin was -45.5% in Q3 2026, reflecting core business profitability. This is down 78.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 87.2 percentage points.

Net Margin
-50.4%
YoY-81.5pp
QoQ-85.4pp
5Y change-72.8pp
10Y change-64.1pp

Incyte Genomics Inc's net profit margin was -50.4% in Q3 2026, showing the share of revenue converted to profit. This is down 81.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 85.4 percentage points.

Return on Equity
-13.9%
YoY-23.0pp
QoQ-23.1pp
5Y change-19.7pp
10Y change-23.9pp

Incyte Genomics Inc's quarterly ROE was -13.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 23.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 23.1 percentage points.

Capital Allocation

R&D Spending
$1.8B
YoY+253.7%
QoQ+246.6%
5Y CAGR+39.8%

Incyte Genomics Inc invested $1.8B in research and development in Q3 2026. This represents an increase of 253.7% from the same quarter a year earlier. Against the prior quarter it is up 246.6%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

INCY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INCY quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$1.6B+14.0%$1.7B+37.7%$1.3B+20.9%$1.5B+27.8%$1.4B+20.0%$1.2B+16.5%$1.1B+19.5%$1.2B+16.3%
Cost of Revenue$108.7M+9.8%$105.0M+33.3%$104.5M+42.8%$121.2M+36.9%$99.0M+15.1%$78.8M+2.8%$73.2M+20.1%$88.5M+26.9%
Gross Profit$1.4B+14.3%$1.6B+38.0%$1.2B+19.2%$1.4B+27.1%$1.3B+20.4%$1.1B+17.5%$979.7M+19.5%$1.1B+15.5%
R&D Expenses$1.8B+253.7%$517.0M+4.5%$515.9M+18.0%$611.4M+31.2%$506.6M-11.6%$494.9M-56.5%$437.3M+1.9%$466.0M+4.8%
SG&A Expenses$364.3M+10.7%$351.7M+6.3%$328.1M+0.7%$390.4M+19.5%$329.1M+6.4%$331.0M+8.2%$325.7M+8.5%$326.7M+13.3%
Operating Income-$708.4M-259.7%$697.9M+31.6%$301.1M+46.8%$335.9M+11.4%$443.5M+203.6%$530.3Mn/m$205.2M+123.3%$301.5M+61.0%
EBITDA-$684.2M-246.3%$724.4M+30.9%$324.9M+42.8%$359.8M+11.0%$467.5M+177.3%$553.2Mn/m$227.5M+99.9%$324.2M+55.1%
Interest Expense$605K+2.2%$582K-2.0%$569K-13.8%$582K+38.9%$592K-23.5%$594K-9.6%$660K+53.5%$419K-47.9%
Income Tax$96.0M+65.0%$165.9M+8.4%$40.3M-47.0%$90.7M-19.4%$58.1M+16.1%$153.0M+179.1%$76.0M+14.1%$112.5M+61.0%
Net Income-$784.8M-285.0%$585.6M+44.6%$303.3M+91.7%$299.3M+48.7%$424.2M+298.4%$405.0Mn/m$158.2M-6.7%$201.2M+0.1%
EPS (Basic)-$3.86-277.9%$2.92+39.7%$1.52+85.4%$1.51+57.3%$2.17+294.5%$2.09n/m$0.82+7.9%$0.96+6.7%
EPS (Diluted)-$3.86-282.9%$2.81+37.7%$1.47+83.7%$1.46+53.7%$2.11+290.7%$2.04n/m$0.80+6.7%$0.95+6.7%
Diluted Shares (Avg)203M+0.9%208M+4.8%207M+4.4%N/A201M+2.9%199M-8.9%198M-12.8%N/A

INCY Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INCY quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$7.3B+15.1%$7.9B+35.2%$7.3B+27.7%$7.0B+27.8%$6.3B+26.3%$5.8B+24.9%$5.7B-19.4%$5.4B-19.7%
Current Assets$5.5B+29.1%$6.0B+65.4%$5.5B+56.4%$5.0B+55.1%$4.3B+52.3%$3.6B+41.9%$3.5B-27.7%$3.2B-30.3%
Cash & Equivalents$3.3B+33.4%$4.0B+103.7%$3.5B+78.2%$3.1B+83.5%$2.5B+88.3%$2.0B+98.0%$1.9B-42.0%$1.7B-47.5%
Short-Term Investments$578.7M+21.9%$553.4M+18.6%$554.7M+18.8%$482.8M+2.7%$474.8M+1.6%$466.8M+1.0%$466.9M-7.4%$470.3M+6.2%
Inventory$134.3M+60.9%$112.5M+34.9%$115.6M+80.7%$101.1M+71.7%$83.4M+18.5%$83.4M-17.2%$64.0M+0.5%$58.9M-6.5%
Accounts Receivable$1.2B+38.1%$1.1B+33.5%$1.1B+27.7%$1.0B+20.1%$895.9M+18.1%$842.9M+14.1%$823.1M+10.4%$853.2M+14.7%
Goodwill$133.0M-14.5%$133.0M-14.5%$133.0M-14.5%$133.0M-14.5%$155.6M0.0%$155.6M0.0%$155.6M0.0%$155.6M0.0%
Total Liabilities$1.6B-2.1%$1.5B-7.4%$1.7B-17.6%$1.8B-10.3%$1.7B-8.8%$1.7B-0.9%$2.1B+19.6%$2.0B+25.4%
Current Liabilities$1.4B+7.4%$1.3B+2.6%$1.5B-13.4%$1.5B-7.7%$1.3B-10.8%$1.3B-4.4%$1.7B+23.2%$1.6B+32.4%
Non-Current Liabilities$206.5M-39.3%$216.1M-41.9%$226.6M-37.3%$275.3M-22.4%$340.4M+0.3%$371.8M+13.5%$361.5M+4.8%$354.8M+0.8%
Total Equity$5.6B+21.3%$6.3B+52.1%$5.6B+53.3%$5.2B+49.9%$4.7B+46.7%$4.2B+39.2%$3.7B-32.0%$3.4B-33.6%
Retained Earnings$317.9Mn/m$1.1Bn/m$517.1Mn/m$213.8Mn/m-$85.5Mn/m-$509.7Mn/m-$914.7M-377.2%-$1.1B-768.9%

Not reported in any period shown, so not listed: Long-Term Investments, Long-Term Debt.

INCY Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INCY quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$675.3M-220.7%$507.7M+1034.7%$369.4M+38.8%$543.3M+42.5%$559.4M+79.9%$44.7Mn/m$266.1M+21.6%$381.2M+158.1%
Depreciation & Amortization$24.2M+0.6%$26.5M+15.5%$23.8M+6.4%$24.0M+5.5%$24.0M+6.7%$22.9M+4.0%$22.4M+1.9%$22.7M+4.5%
Stock-Based Compensation$69.8M+13.3%$67.3M+4.2%$64.1M+5.2%N/A$61.6M-20.9%$64.6M+14.1%$61.0M+2.0%N/A
Investing Cash Flow-$44.3Mn/m-$51.8Mn/m-$88.2M-8140.4%-$37.4Mn/m-$47.4M-223.9%-$18.9M-108.8%$1.1Mn/m-$21.5Mn/m
Financing Cash Flow$13.9Mn/m$65.5Mn/m$84.8Mn/m$137.7M+575.4%-$12.8Mn/m-$11.2Mn/m-$12.7Mn/m$20.4M+5794.2%
Share BuybacksN/AN/AN/A$0n/m$0-100.0%N/AN/A$0n/m

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

INCY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INCY quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin93.0%+0.3pp93.7%+0.2pp91.8%-1.3pp92.0%-0.5pp92.8%+0.3pp93.5%+0.9pp93.0%0.0pp92.5%-0.6pp
Operating Margin-45.5%-78.0pp41.7%-1.9pp23.7%+4.2pp22.3%-3.3pp32.5%+19.6pp43.6%+89.4pp19.5%+9.1pp25.6%+7.1pp
Net Margin-50.4%-81.5pp35.0%+1.7pp23.8%+8.8pp19.9%+2.8pp31.1%+21.7pp33.3%+75.9pp15.0%-4.2pp17.1%-2.8pp
Return on Equity-13.9%-23.0pp9.2%-0.5pp5.4%+1.1pp5.8%-0.1pp9.1%+5.8pp9.7%+24.5pp4.3%+1.2pp5.8%+2.0pp
Return on Assets-10.8%-17.5pp7.4%+0.5pp4.1%+1.4pp4.3%+0.6pp6.7%+4.6pp7.0%+16.5pp2.8%+0.4pp3.7%+0.7pp
Current Ratio3.84+0.6x4.59+1.7x3.68+1.6x3.32+1.3x3.20+1.3x2.85+0.9x2.04-1.4x1.97-1.8x
Liabilities-to-Equity0.29-0.1x0.24-0.2x0.31-0.3x0.35-0.2x0.36-0.2x0.40-0.2x0.57+0.2x0.58+0.3x
Asset Turnover0.210.0x0.210.0x0.170.0x0.220.0x0.220.0x0.210.0x0.18+0.1x0.22+0.1x

Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Incyte Genomics Inc INCY FY2025 $5.1B $1.3B 25.0% $23.4B 75/100
BioNTech BNTX FY2025 $3.4B -$1.3B -39.6% $20.1B 53/100
Roivant Sciences Ltd. ROIV FY2026 $8.3M -$299.8M N/A $28.0B 70/100
Alnylam Pharmaceuticals, Inc. ALNY FY2025 $3.7B $313.7M 8.5% $19.3B 63/100
Revolution Medicines, Inc. RVMD FY2025 $0 -$1.1B N/A $34.9B —
Genmab A/S GMAB FY2025 $3.7B $963.0M 25.9% $31.2B 75/100

Frequently Asked Questions

Incyte Genomics Inc (INCY) reported $5.1B in total revenue for fiscal year 2025. This represents a 21.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Incyte Genomics Inc (INCY) revenue grew by 21.2% year-over-year, from $4.2B to $5.1B in fiscal year 2025.

Yes, Incyte Genomics Inc (INCY) reported a net income of $403.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $1.3B, with a net profit margin of 25.0%.

Incyte Genomics Inc (INCY) reported diluted earnings per share of $6.41 for fiscal year 2025. This represents a 4173.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Incyte Genomics Inc (INCY) had EBITDA of $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Incyte Genomics Inc (INCY) had a gross margin of 92.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Incyte Genomics Inc (INCY) had an operating margin of 29.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Incyte Genomics Inc (INCY) had a net profit margin of 25.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Incyte Genomics Inc (INCY) has a return on equity of 24.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Incyte Genomics Inc (INCY) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Incyte Genomics Inc (INCY) had $7.0B in total assets as of fiscal year 2025, including both current and long-term assets.

Incyte Genomics Inc (INCY) invested $2.1B in research and development during fiscal year 2025.

Incyte Genomics Inc (INCY) had 199M shares outstanding as of fiscal year 2025.

Incyte Genomics Inc (INCY) had a current ratio of 3.32 as of fiscal year 2025, which is generally considered healthy.

Incyte Genomics Inc (INCY) had a liabilities-to-equity ratio of 0.35 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Incyte Genomics Inc (INCY) had a return on assets of 18.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Incyte Genomics Inc (INCY) trades at 57.9x earnings, its market capitalization divided by $403.4M net income, trailing 12 months to September 30, 2026. The market capitalization is $23.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Incyte Genomics Inc (INCY) trades at 3.9x sales, its market capitalization divided by $6.0B revenue, trailing 12 months to September 30, 2026. The market capitalization is $23.4B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Incyte Genomics Inc (INCY) has an Altman Z-Score of 9.93, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Incyte Genomics Inc (INCY) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Incyte Genomics Inc (INCY) has an earnings quality ratio of 1.10x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Incyte Genomics Inc (INCY) has an interest coverage ratio of 623.91x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Incyte Genomics Inc (INCY) scores 75 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Incyte Genomics Inc it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top